Does the sponsor of the clinical trial for the purpose of regulatory approval need to be consistent with the clinical trial approval, notice or filing and publication materials?

Yes; If the clinical trial sponsor is inconsistent with the clinical trial approval, notice or filing and publication materials, when filling in the application for international cooperative scientific research, it is necessary to submit relevant agreements and other supporting materials as attachments to clarify their respective rights and responsibilities.

Suggested Reading

Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation?
Do all medical devices require chemical characterization?
What factors may affect biocompatibility risk when using biological test data from similar devices for…
How should the evaluation of new items in the endpoint table be considered after the implementation of the new…
When combining subchronic and implantation tests in one project, what factors need to be considered, and how can…
How is the endotoxin limit for wound dressing products determined?
Why is the extraction period typically 24 hours in China for cytotoxicity testing?
Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,…
What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can…
For subchronic systemic toxicity studied via implantation, what is the basis for determining the implantation…
GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests…
GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which…

Does The Sponsor Of The Clinical Trial For The Purpose Of Regulatory Approval Need To Be Consistent With The Clinical Trial Approval, Notice Or Filing And Publication Materials?

Suggested Reading